Evidence map›Paper›PMID 41115998›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2025

Elevated sFlt-1/PlGF ratio in women with suspected or confirmed early-onset preeclampsia and super-imposed preeclampsia complicated by HELLP syndrome as well as abnormal umbilical artery Doppler findings and non-reassuring fetal status requiring immediate delivery: a prospective cohort study.

Akihide Ohkuchi, Hirotada Suzuki, Chikako Hirashima, Kayo Takahashi, Manabu Ogoyama, Kenji Horie, Rie Usui, Hironori Takahashi, Hiroyuki Fujiwara, Tatsuo Yamamoto

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Akihide Ohkuchi *Department of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan. okuchi@jichi.ac.jp.
Hirotada Suzuki *Department of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan.
Chikako HirashimaDepartment of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan.
Kayo TakahashiDepartment of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan.
Manabu OgoyamaDepartment of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan.
Kenji HorieDepartment of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan.
Rie UsuiDepartment of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan.
Hironori TakahashiDepartment of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan.
Hiroyuki FujiwaraDepartment of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan.
Tatsuo YamamotoDepartment of Obstetrics and Gynecology, Kasukabe Medical Center, Kasukabe-shi, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to investigate the effects of serum sFlt-1/PlGF ratio levels in women with suspected or confirmed early-onset preeclampsia and super-imposed preeclampsia (PE/SPE) on composite and individual adverse maternal and fetal outcomes, stratified by gestational age at blood sampling (<34, 34-36, and ≥37 weeks). We also evaluated whether serum sFlt-1/PlGF ratio levels influenced the time interval from blood sampling to delivery. This prospective cohort study assessed serum levels of sFlt-1, PlGF, and the sFlt-1/PlGF ratio in women with suspected or confirmed PE/SPE admitted to a tertiary maternal-fetal-neonatal center between 2012 and 2023. Finally, 241 women were analyzed. An elevated sFlt-1/PlGF ratio at <34 weeks of gestation, but not at 34-36 or ≥37 weeks, was significantly associated with composite adverse maternal and fetal outcomes in women with suspected or confirmed PE/SPE. An sFlt-1/PlGF ratio of 400 was identified as the optimal cut-off level for predicting composite adverse maternal and fetal outcomes at <34 weeks. Among women with suspected or confirmed early-onset PE/SPE, HELLP syndrome alone was significantly associated with an sFlt-1/PlGF ratio ≥400. Additionally, the sFlt-1/PlGF ratio was significantly higher in women with HELLP syndrome, abnormal umbilical artery Doppler findings, or non-reassuring fetal status (NRFS) requiring immediate delivery, compared with those without these conditions. Furthermore, the interval from blood sampling to delivery significantly shortened with increasing sFlt-1/PlGF ratio. In conclusion, elevated sFlt-1/PlGF ratios were significantly associated with HELLP syndrome, abnormal umbilical artery Doppler findings, and NRFS requiring immediate delivery in women with suspected or confirmed early-onset PE/SPE. The sFlt-1/PlGF ratio at <34 weeks of gestation, but not at 34-36 or ≥37 weeks, was associated with composite adverse maternal and fetal outcomes in women with suspected or confirmed preeclampsia and super-imposed preeclampsia (PE/SPE). In women with suspected or confirmed early-onset PE/SPE, the sFlt-1/PlGF ratio was significantly higher not only in those with HELLP syndrome, but also in those with abnormal umbilical artery Doppler findings and non-reassuring fetal status (NRFS) requiring immediate delivery. Among women with suspected or confirmed early-onset PE/SPE, time to delivery from blood sampling decreased with increasing sFlt-1/PlGF ratio.

Indexed as

HELLP SyndromePlacenta Growth FactorPre-EclampsiaUmbilical ArteriesVascular Endothelial Growth Factor Receptor-1AdultFemaleGestational AgeHumansPregnancyPregnancy OutcomeProspective StudiesUltrasonography, DopplerUltrasonography, PrenatalFLT1 protein, humanPGF protein, humanPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Adverse outcomesHELLP syndromePlacental growth factorPreeclampsiaSoluble fms-like tyrosine kinase 1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.